Press Releases
Site - Investor Relations
Predictive Oncology Inc. Announces Receipt of Cash Proceeds of $2.2 Million from Exercise of Warrants
In consideration for the immediate exercise of the existing warrants for cash, the exercising holders received new unregistered warrants to purchase up to an aggregate of 1,396,826 shares of common stock at an exercise price of
The Company expects to use the net proceeds from this offering for working capital and general corporate purposes.
The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), and, along with the shares of common stock issuable upon the exercise thereof, have not been registered under the Securities Act, and may not be offered or sold in
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About
Forward-Looking Statements
Certain of the matters discussed in this press release, including the intended use of the proceeds from the transaction described herein, are forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include: we may not be able to continue operating without additional financing; current negative operating cash flows; the terms of any further financing, which may be highly dilutive and may include onerous terms; risks related to the 2019 merger with
Investor Relations Contact:
Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com
Source: Predictive Oncology Inc.